Argonaut Manufacturing Services, a contract development manufacturing organization (CDMO) specializing in aseptic drug product manufacturing and the manufacturing of life science and diagnostic products, has appointed Rick Hancock as Chief Executive Officer (CEO).

Hancock is a biotechnology executive with more than 40 years of leadership experience in CDMOs and pharmaceutical development companies and has served on Argonaut’s Board of Directors for the past nine years. Working closely with the Argonaut management team, he has been instrumental in guiding the company’s evolution from life sciences and diagnostics into drug product manufacturing and now takes over direct leadership responsibility for the organization.

As CEO, Hancock will oversee Argonaut’s continued growth, including the expansion of its Carlsbad, CA campus. In October, Argonaut held a grand opening of its new drug product facility in Carlsbad. This new manufacturing site is equipped with an additional state of the art Annex 1 compliant isolator-based filling line capable of filling vials, prefilled syringes, and cartridges. This investment increases Argonaut’s commercial-scale capacity fivefold, enhancing its ability to serve clients worldwide.

“Argonaut’s future is bright, and our mission remains to help clients overcome complex challenges and deliver life-changing products to patients faster,” Hancock remarked. “By uniting our team’s industry leading technical mastery and customer focus with our expanded capabilities, we strengthen our ability to meet our client’s ongoing needs.”